The IMpower110 study (n=572) found that a PD-L1 (programmed cell death ligand-1) inhibitor is effective as a first-line treatment for advanced NSCLC patients whose tumors have PD-L1 expression on ≥ 1% of tumor cells (9). This evidence concerns the gene CD274 and non-small cell lung carcinoma.